vestommВестник охраны материнства и младенчестваBulletin of maternal and child care3034-395XФГБУ «НИИ ОММ» Минздрава России10.69964/BMCC-2025-2-1-10-20vestomm-57Research ArticleПЕРЕДОВАЯ СТАТЬЯEDITORIALУправление кардиоваскулярными рисками у женщин в пери-и-постменопаузе: глобальная задача здравоохранения (обзор литературы)Cardiovascular risk management in women in peri- and postmenopause: a global health challenge (literature review)https://orcid.org/0009-0002-0045-3264МиняйлоО. А.MinyailoO. A.

Миняйло Ольга Алексеевна — к.м.н., ассистент кафедры кардиологии 

Адрес: ул. 8 Марта, 78а, г. Екатеринбург, 620144

Телефон: +79122863062

Olga A. Minyailo — PhD, Assistant of the Department of Cardiology

Address: st. 8 Marta, 78a, Ekaterinburg, 620144

Phone: +79122863062

mamautia@mail.ruhttps://orcid.org/0000-0002-4090-0578МелкозероваО. А.MelkozerovaO. A.

Мелкозерова Оксана Александровна —доктор медицинских наук, доцент, заместитель директора института по науке

Адрес: ул. Репина, д. 1, г. Екатеринбург, 620028

Телефон: +7 (343) 371 24 27, +7 (922) 219 45 06

Oksana A. Melkozerova — МD, docent, Deputyof Director for Science

Address: st. Repina, 1, Ekaterinburg, 620028

Phone: +7 (922) 219 45 06, +7 (343) 371 24 27

abolmed1@mail.ruhttps://orcid.org/0000-0002-3855-3650СеменовЮ. А.SemenovYu. A.

Семенов Юрий Алексеевич — доктор медицинских наук, Заслуженный врач Российской Федерации, директор

Адрес: ул. Репина, д. 1, г. Екатеринбург, 620028

Рабочий телефон: + 7 (343) 371 87 68

Yuri A. Semenov — Doctor of Medical Sciences,Honored Doctor of the Russian Federation, Director

Address: st. Repina, 1, Ekaterinburg, 620028

Phone: + 7 (343) 371 87 68

u-sirius@mail.ruhttps://orcid.org/0009-0001-0195-0572ГабинскийЯ. Л.GabinskyYa. L.

Габинский Ян Львович — д.м.н., профессор, Заслуженный врач Российской Федерации, заведующий кафедрой кардиологиифедерального государственного бюджетного образовательного учреждения высшегообразования «Уральский ГосударственныйМедицинский Университет» Министерстваздравоохранения Российской Федерации,; главный врач

Адрес: 620144, г. Екатеринбург, ул. 8 Марта, 78

Yan L. Gabinskiy — MD, PhD, Professor, HonoredDoctor of the Russian Federation, Head of theDepartment of Cardiology of the Federal StateBudgetary Educational Institution of HigherEducation “Ural State Medical University” of theMinistry of Health of the Russian Federation, ChiefPhysician 

Address: st. 8 Marta, 78a, Ekaterinburg, 620144

quest@cardio-burg.ruhttps://orcid.org/0000-0003-1709-6187МихельсонА. А.MikhelsonA. A.

Михельсон Анна Алексеевна — доктор медицинских наук, доцент, руководитель отделениясохранения репродуктивной функции заведующая отделением гинекологии

Адрес: ул. Репина, д. 1, г. Екатеринбург, 620028

Телефон: +7 (343) 371-24-27

Anna A. Mikhelson — MD, docent, Head ofdepartment reproductive functions preservation,Head of the Department of Gynecology

Address: st. Repina, 1, Ekaterinburg, 620028

Phone: +7 (343) 371 24 27

ann_tolmik@mail.ruГосударственное бюджетное учреждение здравоохранения Свердловской области «Уральский институт кардиологии»РоссияState Budgetary Healthcare Institution of the Sverdlovsk Region “Ural Institute of Cardiology”Russian FederationФедеральное государственное бюджетное учреждение «Уральский научно-исследовательский институт охраны материнства и младенчества» Министерства Здравоохранения Российской ФедерацииРоссияFederal State Budgetary Institution “Ural Research Institute of Maternity and Child Care” of the Ministry of Health of the Russian FederationRussian Federation202531032025211020Copyright © Миняйло О.А., Мелкозерова О.А., Семенов Ю.А., Габинский Я.Л., Михельсон А.А., 20252025Миняйло О.А., Мелкозерова О.А., Семенов Ю.А., Габинский Я.Л., Михельсон А.А.Minyailo O.A., Melkozerova O.A., Semenov Y.A., Gabinsky Y.L., Mikhelson A.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.vestnikomm.ru/jour/article/view/57

По данным ВОЗ, кардиометаболические расстройства остаются лидирующей причиной смертности в мире в течение уже 20 лет. На долю болезней сердца сегодня приходится 16 % случаев смерти в мире, а в России этот показатель достигает 47%. К сожалению, осведомленность о сердечно-сосудистых заболеваниях (ССЗ) как основной причине смертности остается недостаточной как среди женщин, так и среди врачей. Риск ССЗ у женщин среднего возраста остается недооцененным и, безусловно, требует своевременного междисциплинарного внимания. Цель исследования. Провести литературный анализ баз данных в аспекте изучения проблемы реализации кардиоваскулярных рисков у женщин в пери-и-постменопаузе. Методы исследования. Проведен анализ доказательных данных, которые были опубликованы в 2015‒2025 гг. в электронных библиотеках CochraneLibrary, PubMed, ELibrary, Science Direct, Scopus, Web of Science, Google Scholar, по ключевым словам сердечно-сосудистые заболевания, кардиоваскулярный риск, пери-и-постменопауза, менопаузальная гормональная терапия. Результаты исследования. В обзоре представлены основные детерминанты реализации кардиометаболических и кардиоваскулярных рсков у женщин в пери-и постменопаузе как в аспекте старения, так и в аспекте влияния менопаузальной гормональной терапии. Заключение. Представленные данные убедительно свидетельствуют, что для предотвращения реализации кардиоваскулярного риска у женщин в пери-и-постменопаузе необходимо создание персонифицированной патогенетически аргументированной стратегии лечебно-профилактических мероприятий, основанной на концепции превентивной медицины.

According to WHO, cardiometabolic disorders have remained the leading cause of death in the world for 20 years. Heart diseases account for 16% of deaths worldwide today, reaching 47% in Russia. Unfortunately, awareness of CVD as a leading cause of death remains insufficient among both women and physicians. The risk of CVD in middle-aged women remains underestimated and certainly requires timely interdisciplinary attention. The aim of the study was to conduct a literature review of databases in the context of studying the problem of cardiovascular risk realization in peri and postmenopausal women. Research methods. An analysis of evidence published in 2015-2025 in the Cochrane Library, PubMed, ELibrary, Science Direct, Scopus, Web of Science, Google Scholar electronic libraries was conducted using the keywords cardiovascular diseases, cardiovascular risk, peri and postmenopause, menopausal hormone therapy. Results of the study. The review presents the main determinants of the implementation of cardiometabolic and cardiovascular risks in women in peri and postmenopause both in terms of aging and in terms of the influence of menopausal hormone therapy. Conclusion. The presented data convincingly indicate that in order to prevent the implementation of cardiovascular risk in women in peri and postmenopause, it is necessary to create a personalized pathogenetically substantiated strategy of therapeutic and preventive measures based on the concept of preventive medicine.

сердечно-сосудистые заболеваниякардиоваскулярный рискпери-и-постменопаузаменопаузальная гормональная терапияcardiovascular diseasescardiovascular riskperi- and postmenopausemenopausal hormone therapyReferencesStuenkel C.A. Do we have new preventive strategies for optimizing cardiovascular health in women? Climacteric. 2019;22(2):133–139. https://doi.org/10.1080/13697137.2018.1561665Stuenkel C.A. Do we have new preventive strategies for optimizing cardiovascular health in women? Climacteric. 2019;22(2):133–139. https://doi.org/10.1080/13697137.2018.1561665Cushman M., Shay C., Howard V. et al. Ten-year differences in women’s awareness related to coronary heart disease: results of the 2019 American Heart Association National Survey: a special report from the American Heart Association. Circulation. 2021;143(7):239–248. https://doi.org/10.1161/CIR.0000000000000907Cushman M., Shay C., Howard V. et al. Ten-year differences in women’s awareness related to coronary heart disease: results of the 2019 American Heart Association National Survey: a special report from the American Heart Association. Circulation. 2021;143(7):239–248. https://doi.org/10.1161/CIR.0000000000000907Wenger N.K., Lloyd-Jones D.M., Elkind M.S.V. et al. Call to action for cardiovascular disease in women: epidemiology, awareness, access, and delivery of equitable health care: a presidential advisory from the American Heart Association. American Heart Association. Circulation. 2022;145:1059–1071. https://doi.org/10.1161/CIR.0000000000001071Wenger N.K., Lloyd-Jones D.M., Elkind M.S.V. et al. Call to action for cardiovascular disease in women: epidemiology, awareness, access, and delivery of equitable health care: a presidential advisory from the American Heart Association. American Heart Association. Circulation. 2022;145:1059–1071. https://doi.org/10.1161/CIR.0000000000001071Bello N.A., Merz C.N.B., Cheng S. A scientific imperative as seen through a sharpened lens: sex, gender, and the cardiovascular condition. Circ. Res. 2022;130:433–435. https://doi.org/10.1161/CIRCRESAHA.122.320825Bello N.A., Merz C.N.B., Cheng S. A scientific imperative as seen through a sharpened lens: sex, gender, and the cardiovascular condition. Circ. Res. 2022;130:433–435. https://doi.org/10.1161/CIRCRESAHA.122.320825Luu J.M., Wei J., Shufelt C.L. et al. Clinical Practice Variations in the Management of Ischemia With No Obstructive Coronary Artery Disease. J. Am. Heart Assoc. 2022;11:022573. https://doi.org/10.1161/JAHA.121.022573Luu J.M., Wei J., Shufelt C.L. et al. Clinical Practice Variations in the Management of Ischemia With No Obstructive Coronary Artery Disease. J. Am. Heart Assoc. 2022;11:022573. https://doi.org/10.1161/JAHA.121.022573Shaw L.J., Min J.K., Nasir K. et al. Sex differences in calcified plaque and long-term cardiovascular mortality: observations from the CAC Consortium. Eur. Heart J. 2018;39(41):3727–3735. https://doi.org/10.1093/eurheartj/ehy534Shaw L.J., Min J.K., Nasir K. et al. Sex differences in calcified plaque and long-term cardiovascular mortality: observations from the CAC Consortium. Eur. Heart J. 2018;39(41):3727–3735. https://doi.org/10.1093/eurheartj/ehy534Ibanez B., James S., Agewa S. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardialinfarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 2018;39(2):119–177. https://doi.org/10.1093/eurheartj/ehx393Ibanez B., James S., Agewa S. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardialinfarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 2018;39(2):119–177. https://doi.org/10.1093/eurheartj/ehx393Maas A.H.E.M., Rosano G., Cifkova R. et al. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. Eur. Heart J. 2021;42:967–984. https://doi.org/10.1093/eurheartj/ehaa1044Maas A.H.E.M., Rosano G., Cifkova R. et al. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. Eur. Heart J. 2021;42:967–984. https://doi.org/10.1093/eurheartj/ehaa1044Maas A.H.E.M. Maintaining cardiovascular health: an approach specific to women. Maturitas. 2019;124:68–71. https://doi.org/10.1016/j.maturitas.2019.03.021Maas A.H.E.M. Maintaining cardiovascular health: an approach specific to women. Maturitas. 2019;124:68–71. https://doi.org/10.1016/j.maturitas.2019.03.021Konst R.E., Elias-Smale S.E., Lier A. et al. Different cardio vascular risk factors and psychosocial burden in symptomatic women with and without obstructive coronary artery disease. Eur. J. Prev. Cardiol 2019;26(6):657–659. https://doi.org/10.1177/2047487318814298Konst R.E., Elias-Smale S.E., Lier A. et al. Different cardio vascular risk factors and psychosocial burden in symptomatic women with and without obstructive coronary artery disease. Eur. J. Prev. Cardiol 2019;26(6):657–659. https://doi.org/10.1177/2047487318814298Visseren F.L.J., Mach F., Smulders Y.M. et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 2021;42(34):3227–3337. https://doi.org/10.1093/eurheartj/ehab484Visseren F.L.J., Mach F., Smulders Y.M. et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 2021;42(34):3227–3337. https://doi.org/10.1093/eurheartj/ehab484Couto C.P., Policiano C., Pinto F.J. et al. Endometriosis and cardiovascular disease: A systematic re view and meta-analysis. Maturitas. 2023;171:45–52. https://doi.org/10.1016/j.maturitas.2023.04.001Couto C.P., Policiano C., Pinto F.J. et al. Endometriosis and cardiovascular disease: A systematic re view and meta-analysis. Maturitas. 2023;171:45–52. https://doi.org/10.1016/j.maturitas.2023.04.001Zhao L., Zhu Z., Lou H. et al. Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): a meta-analysis. Oncotarget. 2016;7(23):33715–33721. https://doi.org/10.18632/oncotarget.9553;7:33715-21Zhao L., Zhu Z., Lou H. et al. Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): a meta-analysis. Oncotarget. 2016;7(23):33715–33721. https://doi.org/10.18632/oncotarget.9553;7:33715-21Cho L., Davis M., Elgendy I. et al. Summary of updated recommendations for primary prevention of cardio vascular disease in women: JACC state-of-theart review. J. Am. Coll. Cardiol 2020;75(20):2602–2618. https://doi.org/10.1016/j.jacc.2020.03.060Cho L., Davis M., Elgendy I. et al. Summary of updated recommendations for primary prevention of cardio vascular disease in women: JACC state-of-theart review. J. Am. Coll. Cardiol 2020;75(20):2602–2618. https://doi.org/10.1016/j.jacc.2020.03.060Lia M., Zhub Y., Weid J. et al. The global prevalence of premature ovarian insufficiency: a systematic review and meta-analysis. Climacteric. 2023;26(2):95–102. https://doi.org/10.1080/13697137.2022.2153033Lia M., Zhub Y., Weid J. et al. The global prevalence of premature ovarian insufficiency: a systematic review and meta-analysis. Climacteric. 2023;26(2):95–102. https://doi.org/10.1080/13697137.2022.2153033Santoro N., Roeca C., Peters B.A., Neal-Perry G. The menopause transition: signs, symptoms, and manage ment options. J. Clin. Endocrinol. Metab. 2021;106(1): 1–15. https://doi.org/10.1210/clinem/dgaa764Santoro N., Roeca C., Peters B.A., Neal-Perry G. The menopause transition: signs, symptoms, and manage ment options. J. Clin. Endocrinol. Metab. 2021;106(1): 1–15. https://doi.org/10.1210/clinem/dgaa764Harlow S.D., Gass M., Hall J.E. et al. Executive sum mary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging re productive aging. Climacteric. 2012;15(2):105–114. https://doi.org/10.3109/13697137.2011.650656Harlow S.D., Gass M., Hall J.E. et al. Executive sum mary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging re productive aging. Climacteric. 2012;15(2):105–114. https://doi.org/10.3109/13697137.2011.650656El Khoudary S.R., Greendale G., Crawford S.L. et al. The menopause transition and women’s health at midlife: a progress report from the Study of Women’s Health Across the Nation (SWAN). Menopause. 2019;26(10):1213–1227. https://doi.org/10.1097/GME.0000000000001424El Khoudary S.R., Greendale G., Crawford S.L. et al. The menopause transition and women’s health at midlife: a progress report from the Study of Women’s Health Across the Nation (SWAN). Menopause. 2019;26(10):1213–1227. https://doi.org/10.1097/GME.0000000000001424Bacon E.R., Mishra A., Wang Y. et al. Neuroendocrine aging precedes perimenopause and is regulated by DNA methylation. Neurobiol. Aging 2019;74:213–224. https://doi.org/10.1016/j.neurobiolaging.2018.09.029Bacon E.R., Mishra A., Wang Y. et al. Neuroendocrine aging precedes perimenopause and is regulated by DNA methylation. Neurobiol. Aging 2019;74:213–224. https://doi.org/10.1016/j.neurobiolaging.2018.09.029Carson M.Y., Thurston R.C. Vasomotor symp toms and their links to cardiovascular disease risk. Curr. Opin. Endocr. Metab. Res 2023;30:100448. https://doi.org/10.1016/j.coemr.2023.100448Carson M.Y., Thurston R.C. Vasomotor symp toms and their links to cardiovascular disease risk. Curr. Opin. Endocr. Metab. Res 2023;30:100448. https://doi.org/10.1016/j.coemr.2023.100448Thurston R.C. Symptom reporting, cardiovascular dis ease, and mortality as women age: it is more than menopause. Menopause. 2022;29(12):1355–1356. https://doi.org/10.1097/GME.0000000000002121Thurston R.C. Symptom reporting, cardiovascular dis ease, and mortality as women age: it is more than menopause. Menopause. 2022;29(12):1355–1356. https://doi.org/10.1097/GME.0000000000002121Юренева С.В., Аверкова В.Г. Вазомоторные симптомы в менопаузе: центральные триггеры, эффекторы и новые возможности патогенетической терапии. Российский вестник акушера-гинеколога 2018;5:43–48. [Yureneva S.V., Averkova V.G. Vasomotor symptoms in menopause: central triggers, effectors and new possibilities of pathogenetic therapy. Russian Bulletin of Obstetrician-Gynecologist 2018;5:43–48.] https://doi.org/10.17116/rosakush20181805143Юренева С.В., Аверкова В.Г. Вазомоторные симптомы в менопаузе: центральные триггеры, эффекторы и новые возможности патогенетической терапии. Российский вестник акушера-гинеколога 2018;5:43–48. [Yureneva S.V., Averkova V.G. Vasomotor symptoms in menopause: central triggers, effectors and new possibilities of pathogenetic therapy. Russian Bulletin of Obstetrician-Gynecologist 2018;5:43–48.] https://doi.org/10.17116/rosakush20181805143El Khoudary S.R., Aggarwal B., Beckie T.M. et al. Menopause transition and cardiovascular dis ease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. Circulation. 2020;(25);142:506–532. https://doi.org/10.1161/CIR.0000000000000912El Khoudary S.R., Aggarwal B., Beckie T.M. et al. Menopause transition and cardiovascular dis ease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. Circulation. 2020;(25);142:506–532. https://doi.org/10.1161/CIR.0000000000000912Nappi R.E., Siddiqui E., Todorova L. et al. Prevalence and quality-of-life burden of vasomotor symptoms associ ated with menopause: A European cross-sectional sur vey. Maturitas. 2023;167:66–74. https://doi.org/10.1016/j.maturitas.2022.09.006Nappi R.E., Siddiqui E., Todorova L. et al. Prevalence and quality-of-life burden of vasomotor symptoms associ ated with menopause: A European cross-sectional sur vey. Maturitas. 2023;167:66–74. https://doi.org/10.1016/j.maturitas.2022.09.006Miller V.M., Kling J.M., Files J.A. et al. What’s in a name: are menopausal ‘‘hot flashes’’ a symptom of menopause or a manifestation of neurovascular dysregulation? Menopause. 2018;25(6):700–703. https://doi.org/10.1097/GME.000000000000106Miller V.M., Kling J.M., Files J.A. et al. What’s in a name: are menopausal ‘‘hot flashes’’ a symptom of menopause or a manifestation of neurovascular dysregulation? Menopause. 2018;25(6):700–703. https://doi.org/10.1097/GME.000000000000106Thurston R.C., Carroll J.E., Levine M. et al. Vasomotor symptoms and accelerated epigenetic aging in the Women’s Health Initiative (WHI). J. Clin. Endocrinol. Metab. 2020;105(4):1221–1227. https://doi.org/10.1210/clinem/dgaa081Thurston R.C., Carroll J.E., Levine M. et al. Vasomotor symptoms and accelerated epigenetic aging in the Women’s Health Initiative (WHI). J. Clin. Endocrinol. Metab. 2020;105(4):1221–1227. https://doi.org/10.1210/clinem/dgaa081Muka T., Oliver-Williams C., Colpani V. et al. Association of vasomotor and other menopausal symptoms with risk of cardiovascular disease: a systematic re view and meta-analysis. PLoS One. 2016;11:0157417. https://doi.org/10.1371/journal.pone.0157417Muka T., Oliver-Williams C., Colpani V. et al. Association of vasomotor and other menopausal symptoms with risk of cardiovascular disease: a systematic re view and meta-analysis. PLoS One. 2016;11:0157417. https://doi.org/10.1371/journal.pone.0157417Vogel B., Acevedo M., Appelman Y. et al. The Lancet women and cardiovascular disease commission: reducing the global burden by 2030. Lancet. 2021;397(10292): 2385– 2438. https://doi.org/10.1016/S0140-6736(21)00684-XVogel B., Acevedo M., Appelman Y. et al. The Lancet women and cardiovascular disease commission: reducing the global burden by 2030. Lancet. 2021;397(10292): 2385– 2438. https://doi.org/10.1016/S0140-6736(21)00684-XSamargandy S., Matthews K.A., Brooks M.M. et al. Trajectories of blood pressure in midlife women: does menopause matter? Circ. Res. 2022;130: 312–322. https://doi.org/10.1161/CIRCRESAHA.121.319424Samargandy S., Matthews K.A., Brooks M.M. et al. Trajectories of blood pressure in midlife women: does menopause matter? Circ. Res. 2022;130: 312–322. https://doi.org/10.1161/CIRCRESAHA.121.319424Cifkova R., Pitha J., Krajcoviechova A., Kralikova E. Is the impact of conventional risk factors the same in men and women? Plea for a more gender-specific approach. Int. J. Cardiol. 2019;286:214–219. https://doi.org/10.1016/j.ijcard.2019.01.039Cifkova R., Pitha J., Krajcoviechova A., Kralikova E. Is the impact of conventional risk factors the same in men and women? Plea for a more gender-specific approach. Int. J. Cardiol. 2019;286:214–219. https://doi.org/10.1016/j.ijcard.2019.01.039Cifkova R., Pitha J., Krajcoviechova A., Kralikova E. Is the impact of conventional risk factors the same in men and women? Plea for a more gender-specific approach. Int. J. Cardiol. 2019;286:214–219. https://doi.org/10.1016/j.ijcard.2019.01.039Cifkova R., Pitha J., Krajcoviechova A., Kralikova E. Is the impact of conventional risk factors the same in men and women? Plea for a more gender-specific approach. Int. J. Cardiol. 2019;286:214–219. https://doi.org/10.1016/j.ijcard.2019.01.039Samargandy S., Matthews K.A., Brooks M.M. et al. Arterial stiffness accelerates within 1 year of the final menstrual period: the SWAN Heart Study. Arterioscler. Thromb. Vasc. Biol. 2020;40:1001–1008. https://doi.org/10.1161/ATVBAHA.119.313622Samargandy S., Matthews K.A., Brooks M.M. et al. Arterial stiffness accelerates within 1 year of the final menstrual period: the SWAN Heart Study. Arterioscler. Thromb. Vasc. Biol. 2020;40:1001–1008. https://doi.org/10.1161/ATVBAHA.119.313622Hildreth K.L., Ozeme C., Kohrt W.M. et al. Vascular dysfunction across the stages of the menopausal transition is associated with menopausal symptoms and quality of life. Menopause. 2018;25(9):1011–1019. https://doi.org/10.1097/GME.0000000000001112Hildreth K.L., Ozeme C., Kohrt W.M. et al. Vascular dysfunction across the stages of the menopausal transition is associated with menopausal symptoms and quality of life. Menopause. 2018;25(9):1011–1019. https://doi.org/10.1097/GME.0000000000001112Thurston R.C., Karvonen-Gutierrez C.A., Derby C.A. et al. Menopause versus chronologic aging: their roles in women’s health. Menopause. 2018;25: 849–854. https://doi.org/10.1097/GME.0000000000001143Thurston R.C., Karvonen-Gutierrez C.A., Derby C.A. et al. Menopause versus chronologic aging: their roles in women’s health. Menopause. 2018;25: 849–854. https://doi.org/10.1097/GME.0000000000001143Ding M., Manson J.E. HDL-C and arterial calcifica tion in midlife women: does an HDL paradox exist? Menopause. 2021;28(3):231–233. https://doi.org/10.1097/GME.0000000000001734Ding M., Manson J.E. HDL-C and arterial calcifica tion in midlife women: does an HDL paradox exist? Menopause. 2021;28(3):231–233. https://doi.org/10.1097/GME.0000000000001734Kronenberg F., Mora S., Stroes E.S.G. et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur. Heart J. 2022;43(39):3925–3946. https://doi.org/10.1093/eurheartj/ehac361Kronenberg F., Mora S., Stroes E.S.G. et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur. Heart J. 2022;43(39):3925–3946. https://doi.org/10.1093/eurheartj/ehac361DePree B., Houghton K., Shiozawa A. et al. Treatment and resource utilization for menopausal symptoms in the United States: a retrospective review of re al-world evidence from US electronic health records.Menopause. 2023;30(1):70–79. https://doi.org/10.1097/GME.0000000000002095DePree B., Houghton K., Shiozawa A. et al. Treatment and resource utilization for menopausal symptoms in the United States: a retrospective review of re al-world evidence from US electronic health records.Menopause. 2023;30(1):70–79. https://doi.org/10.1097/GME.0000000000002095Mehta J., Kling J.M., Manson J.E. Risks, benefits, and treatment modalities of menopausal hormone therapy: current concepts. Front. Endocrinol. 2021;12:564781. https://doi.org/10.3389/fendo.2021.564781Mehta J., Kling J.M., Manson J.E. Risks, benefits, and treatment modalities of menopausal hormone therapy: current concepts. Front. Endocrinol. 2021;12:564781. https://doi.org/10.3389/fendo.2021.564781Manson J.E., Aragaki A.K., Rossouw J.E. et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women’s Health Initiative randomized trials. JAMA. 2017;318:927–938. https://doi.org/10.1001/jama.2017.11217Manson J.E., Aragaki A.K., Rossouw J.E. et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women’s Health Initiative randomized trials. JAMA. 2017;318:927–938. https://doi.org/10.1001/jama.2017.11217Miller V.M., Naftolin F., Asthana S. et al. The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned? Menopause. 2019;26(9):1071–1084. https://doi.org/10.1097/GME.0000000000001326Miller V.M., Naftolin F., Asthana S. et al. The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned? Menopause. 2019;26(9):1071–1084. https://doi.org/10.1097/GME.0000000000001326Faubion S.S., Crandall C.J., Davis L. et al. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794. https://doi.org/10.1097/GME.0000000000002028Faubion S.S., Crandall C.J., Davis L. et al. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794. https://doi.org/10.1097/GME.0000000000002028El Khoudary S.R., Venugopal V., Manson J.E. et al. Heart fat and carotid artery atherosclerosis progression in re cently menopausal women: impact of menopausal hor mone therapy: the KEEPS trial. Menopause. 2020;27:255– 262. https://doi.org/10.1097/GME.0000000000001472El Khoudary S.R., Venugopal V., Manson J.E. et al. Heart fat and carotid artery atherosclerosis progression in re cently menopausal women: impact of menopausal hor mone therapy: the KEEPS trial. Menopause. 2020;27:255– 262. https://doi.org/10.1097/GME.0000000000001472Slopien R., Wender-Ozegowska E., Rogowicz-Frontczak A. et al. Menopause and diabetes: EMAS clinical guide. Maturitas. 2018;117:6–10. https://doi.org/10.1016/j.matu-ritas.2018.08.009Slopien R., Wender-Ozegowska E., Rogowicz-Frontczak A. et al. Menopause and diabetes: EMAS clinical guide. Maturitas. 2018;117:6–10. https://doi.org/10.1016/j.matu-ritas.2018.08.009Gambacciani M., Cagnacci A., Lello S. Hormone replace ment therapy and prevention of chronic conditions. Climacteric. 2019;22(3):.303–306. https://doi.org/10.1080/13697137.2018.1551347Gambacciani M., Cagnacci A., Lello S. Hormone replace ment therapy and prevention of chronic conditions. Climacteric. 2019;22(3):.303–306. https://doi.org/10.1080/13697137.2018.1551347Dinger J., Bardenheuer K., Heinemann K. Drospirenone plus estradiol and the risk of serious cardiovascular events in postmenopausal women. Climacteric. 2016;19(4):349– 356. https://doi.org/10.1080/13697137.2016.1183624Dinger J., Bardenheuer K., Heinemann K. Drospirenone plus estradiol and the risk of serious cardiovascular events in postmenopausal women. Climacteric. 2016;19(4):349– 356. https://doi.org/10.1080/13697137.2016.1183624

The authors declare that there are no conflicts of interest present.